LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Coxon, CR
Publisher: Impact Journals
Journal: Oncotarget
Languages: English
Types: Article
Subjects: small molecule inhibitors, QD, cancer, RM, Research Paper, Nek2, structure-guided design
Nek2 (NIMA-related kinase 2) is a cell cycle-dependent serine/threonine protein kinase that regulates centrosome separation at the onset of mitosis. Overexpression of Nek2 is common in human cancers and suppression can restrict tumor cell growth and promote apoptosis. Nek2 inhibition with small molecules, therefore, offers the prospect of a new therapy for cancer. To achieve this goal, a better understanding of the requirements for selective-inhibition of Nek2 is required. 6-Alkoxypurines were identified as ATP-competitive inhibitors of Nek2 and CDK2. Comparison with CDK2-inhibitor structures indicated that judicious modification of the 6-alkoxy and 2-arylamino substituents could achieve discrimination between Nek2 and CDK2. In this study, a library of 6-cyclohexylmethoxy-2-arylaminopurines bearing carboxamide, sulfonamide and urea substituents on the 2-arylamino ring was synthesized. Few of these compounds were selective for Nek2 over CDK2, with the best result being obtained for 3-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)-N,N-dimethylbenzamide (CDK2 IC50 = 7.0 ?M; Nek2 IC50 = 0.62 ?M) with >10-fold selectivity. Deletion of the 6-substituent abrogated activity against both Nek2 and CDK2. Nine compounds containing an (E)-dialkylaminovinyl substituent at C-6, all showed selectivity for Nek2, e.g. (E)-6-(2-(azepan-1-yl)vinyl)-N-phenyl-9H-purin-2-amine (CDK2 IC50 = 2.70 ?M; Nek2 IC50 = 0.27 ?M). Structural biology of selected compounds enabled a partial rationalization of the observed structure activity relationships and mechanism of Nek2 activation. This showed that carboxamide 11 is the first reported inhibitor of Nek2 in the DFG-in conformation.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Chan JY. A clinical overview of centrosome amplification in human cancers. Int. J. Biol. Sci., 2011; 7:1122-1144.
    • 2. Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J., 1998; 17:470-481.
    • 3. Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene 2002; 21:6184-6194.
    • 4. Mardin BR, Schiebel E. Breaking the ties that bind: new advances in centrosome biology. J. Cell Biol., 2012; 197:11-18.
    • 5. Kim S, Lee K, Choi JH, Ringstad N, Dynlacht BD, Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle. Nat. commun., 2015; 6:8087.
    • 6. Examples include: (a) Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of Nek2 is associated with drug resistance in ovarian cancer. Oncol. Rep., 2014; 31: 745-754; (b) Neal CP, Fry AM, Moreman C, McGregor A, Garcea G, Berry DP, Manson MM. Overexpression of the Nek2 kinase in colorectal cancer correlates with beta-catenin relocalization and shortened cancer-specific survival. J. Surg. Oncol., 2014; 110: 828-838; (c) Zeng YR, Han ZD, Wang C, Cai C, Huang YQ, Luo HW, Liu ZZ, Zhuo YJ, Dai QS, Zhao HB, Liang YX. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer. BMC Urol., 2015; 1: 90; (d) Wubetu GY, Morine Y, Teraoku H, Yoshikawa M, Ishikawa D, Yamada S, Ikemoto T, Saito UU, Imura S, Shimada M. High Nek2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy. Anticancer res., 2016; 36: 757-762; (e) Hayward DG, Clarke RB, Faragher AJ, Pillai MR., Hagan IM, Fry AM. The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer. Cancer Res. 2004; 64:7370-7376.
    • 7. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L. Nek2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell, 2013; 23:48-62.
    • 8. Cappello P, Blaser H, Gorrini C, Lin DCC, Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA, Youngson B. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene, 2014; 33:2375-2384.
    • 9. Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguch, M. Nek2 as an Effective Target for Inhibition of Tumorigenic Growth and Peritoneal Dissemination of Cholangiocarcinoma. Cancer Res. 2007; 67:9637-9642.
    • 10. Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci. 2010; 101:1163-1169.
    • 11. Whelligan DK, Solanki S, Taylor D, Thomson DW, Cheung KMJ, Boxall K, Mas-Droux C, Barillari C, Burns S, Grummitt CG, Collins I, van Montfort RLM, Aherne GW, Bayliss R, Hoelder S. Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization. J. Med. Chem. 2010; 53:7682-7698.
    • 12. Solanki S, Innocenti P, Mas-Droux C, Boxall K, Barillari C, van Montfort RLM, Aherne GW, Bayliss R, Hoelder S. Benzimidazole Inhibitors Induce a DFG-Out Conformation of Never in Mitosis Gene A-Related Kinase 2 (Nek2) without Binding to the Back Pocket and Reveal a Nonlinear Structure−Activity Relationship. J. Med. Chem. 2011; 54:1626-1639.
    • 13. Innocenti P, Cheung KMJ, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, Fry AM, Hoelder S. Design of Potent and Selective Hybrid Inhibitors of the Mitotic Kinase Nek2: Structure-Activity Relationship, Structural Biology, and Cellular Activity. J. Med. Chem. 2012; 55:3228-3241.
    • 14. Hayward DG, Newbatt Y, Pickard L, Byrne E, Mao G, Burns S, Sahota NK, Workman P, Collins I, Aherne W, Fry AM. Identification by High-Throughput Screening of Viridin Analogs as Biochemical and Cell-Based Inhibitors of the Cell Cycle-Regulated Nek2 Kinase. J. Biomol. Screening 2010; 15:918-927.
    • 15. Henise JC, Taunton J. Irreversible Nek2 Kinase Inhibitors with Cellular Activity. J. Med. Chem. 2011; 54:4133-4146.
    • 16. Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles. J. Med. Chem. 2000; 43:2797-2804.
    • 17. (a) Whitfield HJ, Griffin RJ, Hardcastle IR, Henderson A, Meneyrol J, Mesguiche V, Sayle KL, Golding BT. Facilitation of addition-elimination reactions in pyrimidines and purines using TFA in trifluoroethanol. Chem. Commun. 2003; 2802-2803.
    • 18. Carbain B, Coxon CR, Lebraud H, Elliott KJ, Matheson CJ, Meschini E, Roberts AR, Turner DM, Wong C, Cano C, Griffin RJ. Trifluoroacetic Acid in 2, 2, 2-Trifluoroethanol Facilitates SNAr Reactions of Heterocycles with Arylamines. Chem Eur J. 2014; 20:2311-2317.
    • 19. Lee HJ, Choi YS, Lee KB, Park J, Yoon CJ. Hydrogen bonding abilities of thioamide. J. Chem. Phys. A, 2002; 106:7010-7017.
    • 20. Loev B, Kormendy MF. An Improved Synthesis of Carbamates. J. Org. Chem. 1963; 28:3421-3426.
    • 21. Jencks WP, Oakenfull DG, Salvesen K. Reactions of acetylimidazole and acetylimidazolium ion with nucleophilic reagents. Mechanisms of catalysis. J. Am. Chem. Soc. 1971; 93:188-194.
    • 22. Woodman EK, Chaffey JGK, Hopes PA, Hose DRJ, Gilday JP. N,N'-Carbonyldiimidazole-Mediated Amide Coupling: Significant Rate Enhancement Achieved by Acid Catalysis with Imidazole·HCl. Org. Process Res. Dev. 2009; 13:106-113.
    • 23. Beach JW, Kim HO, Jeong LS, Nampalli S, Islam Q, Ahn SK, Babu JR, Chu CK. A Highly Stereoselective Synthesis of Anti-HIV 2',3'-dideoxy- and 2',3'-didehydro-2',3'- dideoxynucleosides. J. Org. Chem. 1992; 57:3887-3894.
    • 24. Baumgarten HE, Petersen JM. Reactions of Amines. V. Synthesis of α-Amino Ketones. J. Am. Chem. Soc., 1960; 82:463-468.
    • 25. Kos NJ, Jongejan H, Van Der Plas HC. Deamination, Involving Ring Opening, in Reactions of 1-Aminopurinium Mesitylenesulfonates with MeOHic Ammonia. Tetrahedron 1987; 43:4841-4848.
    • 26. Kuchar M, Pohl R, Votruba I, Hocek M. Synthesis of Purines Bearing Functionalized C-Substituents by the Conjugate Addition of Nucleophiles to 6-Vinylpurines and 6-Ethynylpurines. Eur. J. Org. Chem. 2006; 5083-5098.
    • 27. Kuchar M, Hocek M, Pohl R, Votruba I, Shih IH, Mabery E, Mackman R, Synthesis, cytostatic, and antiviral activity of novel 6-[2-(dialkylamino)ethyl]-, 6-(2-alkoxyethyl)-, 6-[2-(alkylsulfanyl)ethyl]-, and 6-[2-(dialkylamino) vinyl]purine Nucleosides. Bioorg. Med. Chem. 2008; 16:1400-1424.
    • 28. Hardcastle IR, Arris CE, Bentley J, Boyle T, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury P, Menyerol J, Mesguiche V, Newell DR, Noble MEM, Pratt DJ, Wang LZ, Whitfield H. N2-Substituted O6- Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2, J. Med. Chem. 2004; 47:3710-3722.
    • 29. Copeland RA. Evaluation of Enzyme Inhibitors in Drug Discovery, 2005; Wiley & Sons, Hoboken, New Jersey.
    • 30. Westwood I, Cheary DM, Baxter JE, Richards MW, van Montfort RL, Fry AM, Bayliss R. Insights into the conformational variability and regulation of human Nek2 kinase. J. Mol. Biol. 2009; 386:476-485.
    • 31. Kornev AP, Taylor SS, Ten Eyck LF. A helix scaffold for the assembly of active protein kinases. Proc. Natl. Acad. Sci. USA. 2008; 105:14377-14382.
    • 32. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci, USA, 2005; 102:7665-7670.
    • 33. Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK. Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor, Receptor-2 Kinase Activity. J. Med. Chem. 2005; 48:1107-1131.
    • 34. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, Rabindran SK. Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3- carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2). J. Med. Chem. 2003; 46:49-63.
  • No related research data.
  • No similar publications.
  • BioEntity Site Name
    2w5aProtein Data Bank

Share - Bookmark

Funded by projects

  • WT

Cite this article